Patents Examined by Chang-Yu Wang
  • Methods of screening compounds for the fibril formation of A? peptides based on a decreased trimer/monomer ratio of a chaperone protein
    Patent number: 9522170
    Abstract: A method involves screening a candidate compound for activity in the treatment of a condition associated with formation of amyloid protein fibrils in a mammal, such as Alzheimer's disease. It is determined whether the trimer/monomer ratio of a chaperone protein is decreased in the presence of the candidate compound. The chaperone protein is or has a high identity to the Brichos domains of Bri2, Bri3 or proSP-C from human. Monomers of the chaperone proteins and/or compounds that promote formation of these monomers are useful for medical treatment of the condition.
    Type: Grant
    Filed: March 30, 2012
    Date of Patent: December 20, 2016
    Assignee: ALPHABETA AB
    Inventors: Jan Johansson, Jenny Presto
  • Detection of pathogenic abeta using an epitope protection assay
    Patent number: 9523697
    Abstract: The invention relates to an epitope protection assay for use in diagnosis, prognosis and therapeutic intervention in diseases, for example, involving polypeptide aggregation, such as prion infections. The methods of the invention first block accessible polypeptide target epitope with a blocking agent. After denaturation of the polypeptide, a detecting agent is used to detect protein with target epitope that was inaccessible during contact with the blocking agent.
    Type: Grant
    Filed: October 22, 2010
    Date of Patent: December 20, 2016
    Assignee: PROMIS NEUROSCIENCES Inc.
    Inventors: Neil Cashman, Marty Lehto
  • Human antibodies to GFR ?3 and methods of treating pain associated with osteoarthritis or bone cancer
    Patent number: 9522185
    Abstract: The present invention provides antibodies that bind to human GFR?3 and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human GFR?3. The antibodies of the invention are useful for the treatment of diseases and disorders associated with one or more GFR?3 biological activities, including the treatment of acute or chronic pain conditions, or inflammatory conditions.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: December 20, 2016
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Susan D. Croll, Lynn Macdonald, Andrew J. Murphy
  • Method to treat migraines using CGRP antibodies
    Patent number: 9505838
    Abstract: The present invention provides human engineered calcitonin gene related peptide (CGRP) antibodies or antigen-binding fragment thereof. In addition, the present invention provides the use of the human engineered calcitonin gene related peptide (CGRP) antibodies or antigen-binding fragment thereof for the treatment of osteoarthritis pain.
    Type: Grant
    Filed: June 4, 2015
    Date of Patent: November 29, 2016
    Assignee: Eli Lilly and Company
    Inventors: Barrett Allan, Robert Jan Benschop, Mark Geoffrey Chambers, Ryan James Darling
  • Methods of treating chronic simple glaucoma with ophthalmic preparations based on BDNF (brain-derived neurotrophic factor)
    Patent number: 9387164
    Abstract: The present invention relates to ophthalmic preparations in the form of eyedrops based on BDNF (Brain-Derived Neurotrophic Factor). Said preparations can be administered topically to the intact eye surface, and are useful in the prevention and treatment of neurodegenerative disorders of the retina, optic nerve, lateral geniculate body and visual cortex, in order to prevent reduction of visual capacity and restore the normal visual function.
    Type: Grant
    Filed: November 12, 2010
    Date of Patent: July 12, 2016
    Assignee: HMFRA HUNGARY LIMITED LIABILITY COMPANY
    Inventors: Luciano Domenici, Luca Giovannini, Marco Sanso′
  • Disease-associated proteins
    Patent number: 9353162
    Abstract: Disclosed are methods and compositions for early diagnosis, monitoring and treatment of an ocular disorder. In particular, the invention relates to a novel protein, that is differentially transcribed and expressed in subjects suffering from retinal dystrophies and the like, such as retinal dystrophy and age-related macular degeneration compared with healthy subjects, antibodies which recognize this protein, and methods for diagnosing such conditions.
    Type: Grant
    Filed: December 17, 2012
    Date of Patent: May 31, 2016
    Assignees: NOVARTIS AG, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Thirry Léveillard, Jose Alain Sahel, Saddek Mohand-Said, Olivier Poch, David Hicks, Carlos Alvarez
  • N-11 truncated amyloid-beta A?11-x monoclonal antibodies and compositions
    Patent number: 9329189
    Abstract: This invention relates to antibodies, including specified portions or variants, specific for at least the human Amyloid-beta 11 N-terminal site, i.e. A?11-x peptides. It further provides methods of making and using said antibodies, including therapeutic formulations, administration and devices.
    Type: Grant
    Filed: September 9, 2003
    Date of Patent: May 3, 2016
    Assignee: Janssen Pharmaceutica NV
    Inventors: Marc Hubert Mercken, Marc Maria Pierre Vandermeeren
  • Human laminin ?2 chain LG3 domain and active peptides promoting cell adhesion, spreading, migration, and neurite outgrowth
    Patent number: 9314510
    Abstract: The present invention relates to human laminin ?2 chain LG3 domain and active peptides promoting cell adhesion, spreading, migration, and neurite outgrowth. More particularly, it was found that when nerve cells are incubated using human laminin ?2 chain LG3 domain and active peptides in the LG3 domain, cell adhesion, spreading, migration, and neurite outgrowth of nerve cells promote and the promotion of cell adhesion, spreading, migration, and neurite outgrowth of nerve cells are integrin-mediated and achieved by the activation of PKC? and FAK phosphorylation. Thus, the present invention can be very useful for researches on cell adhesion, spreading, migration, and neurite outgrowth activities of cells which are focused on nerve cells and mediated by various extracellular matrix proteins including laminin, manufacture of artificial nerve conduits, burns treatment, wounds treatment, and tissue regeneration.
    Type: Grant
    Filed: March 12, 2012
    Date of Patent: April 19, 2016
    Assignee: SNU R&DB Foundation
    Inventor: Byung-Moo Min
  • Micronized device for the delivery of biologically active molecules and methods of use thereof
    Patent number: 9265814
    Abstract: The invention provides micronized encapsulated cell therapy devices that are capable of delivering a biologically active molecule to the eye. Also provided are methods of using the same to deliver biologically active molecules to the eye and to treat ophthalmic disorders in patients suffering there from.
    Type: Grant
    Filed: December 18, 2006
    Date of Patent: February 23, 2016
    Assignee: Neurotech USA, INC.
    Inventors: Konrad Kauper, Weng Tao, Paul Stabila
  • Methods of treating retinal nerve fiber layer degeneration with monoclonal antibodies against a retinal guidance molecule (RGM) protein
    Patent number: 9175075
    Abstract: The present application describes RGM A binding proteins, particularly monoclonal antibodies, and in particular CDR grafted, humanized versions thereof, which have the ability to bind to RGM A and prevent binding of RGM proteins to RGM A receptor and other RGM A binding proteins, and therefore neutralize the function of RGM A, for use in the treatment of retinal nerve fiber layer (RNFL) degeneration as well as methods of therapeutically or prophylactically treating a mammal against RNFL degeneration.
    Type: Grant
    Filed: December 8, 2010
    Date of Patent: November 3, 2015
    Assignee: AbbVie Deutschland GmbH & Co. KG
    Inventor: Bernhard K. Mueller
  • Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type
    Patent number: 9102752
    Abstract: The present disclosure is directed to individual A? peptide immunogen constructs, peptide compositions comprising these A? peptide immunogen constructs and mixtures thereof, pharmaceutical compositions including vaccine formulations comprising these A? peptide immunogen constructs, with the individual A? peptide immunogen constructs having the N-terminus of the A? peptide as the B cell (B) epitopes linked through spacer residue(s) to heterologous T helper cell (Th) epitopes derived from pathogen proteins that act together to stimulate the generation of highly specific antibodies directed against the N-terminus of the A? peptide offering protective immune responses to patients at risk for, or with, Alzheimer's Disease.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: August 11, 2015
    Assignee: UNITED BIOMEDICAL, INC.
    Inventor: Chang Yi Wang
  • Antibody specific for apolipoprotein and methods of use thereof
    Patent number: 9102717
    Abstract: The present disclosure provides synthetic antibodies specific for an epitope present on an apolipoprotein E polypeptide. The antibodies are useful in various treatment, diagnostic, and monitoring applications, which are also provided.
    Type: Grant
    Filed: February 25, 2011
    Date of Patent: August 11, 2015
    Assignee: THE J. DAVID GLADSTONE INSTITUTES
    Inventors: Yadong Huang, Qin Xu, Thu Nga Bien-Ly, Karl H. Weisgraber, Ligong Chen, Clare Peters-Libeu
  • Method of biasing implanted human neural stem cells away from differentiation into glial cells by (+)phenserine to modulate the concentration of soluble ?APP in tissue or CSF
    Patent number: 9095573
    Abstract: Disclosed herein are methods and materials for promoting neurogenesis of endogenous and transplanted stem cells. Specifically exemplified herein are methods that comprise transplanting neural stem cells in conjunction with a regimen of (+)phenserine treatment.
    Type: Grant
    Filed: August 1, 2006
    Date of Patent: August 4, 2015
    Inventors: Kiminobu Sugaya, Amelia Marutle, Young Don Kwak
  • CGRP antibodies
    Patent number: 9073991
    Abstract: The present invention provides human engineered calcitonin gene related peptide (CGRP) antibodies or antigen-binding fragment thereof. In addition, the present invention provides the use of the human engineered calcitonin gene related peptide (CGRP) antibodies or antigen-binding fragment thereof for the treatment of osteoarthritis pain.
    Type: Grant
    Filed: June 7, 2011
    Date of Patent: July 7, 2015
    Assignee: Eli Lilly and Company
    Inventors: Barrett Allan, Robert Jan Benschop, Mark Geoffrey Chambers, Ryan James Darling
  • Cellular therapy for ocular degeneration
    Patent number: 9074189
    Abstract: Compositions and methods applicable to cell-based or regenerative therapy for ophthalmic diseases and disorders comprising mesenchymal stem cells, particularly those characterized by the expression of at least one of the following surface markers: CD29, CD44, CD105 or CD166, and the lack of expression of at least one of CD14, CD34 or CD45.
    Type: Grant
    Filed: June 2, 2006
    Date of Patent: July 7, 2015
    Assignee: Janssen Biotech, Inc.
    Inventor: Sanjay Mistry
  • Human antibodies to GFR?3 and methods of use thereof
    Patent number: 8968736
    Abstract: The present invention provides antibodies that bind to human GFR?3 and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human GFR?3. The antibodies of the invention are useful for the treatment of diseases and disorders associated with one or more GFR?3 biological activities, including the treatment of acute or chronic pain conditions, or inflammatory conditions.
    Type: Grant
    Filed: August 21, 2013
    Date of Patent: March 3, 2015
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Susan D. Croll, Lynn Macdonald, Andrew J. Murphy
  • Method for increasing natriuresis or diuresis by isoforms of brain natriuretic peptide
    Patent number: 8912137
    Abstract: Methods and materials for diagnosing and treating heart conditions (e.g., heart failure) and kidney conditions (e.g., kidney failure) are described.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: December 16, 2014
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Shuchong Pan, Robert D. Simari
  • Neuromyelitis optica autoantibodies as a marker for neoplasia
    Patent number: 8889102
    Abstract: The present invention provides for methods and materials for diagnosing and treating neuromyelitis optica (NMO).
    Type: Grant
    Filed: September 19, 2008
    Date of Patent: November 18, 2014
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Vanda A. Lennon, Sean J. Pittock
  • Method for expansion of human corneal endothelial cells
    Patent number: 8889415
    Abstract: A method for expanding human corneal endothelial cells includes: (a) providing an amniotic membrane with or without amniotic cells, wherein the amniotic membrane has an extracellular matrix; (b) placing onto the amniotic membrane, a sheet of endothelial layer, or a cell suspension including human corneal endothelial stem cells; and (c) culturing the corneal endothelial cells on the amniotic membrane for a duration sufficient for the corneal endothelial stem cells to expand to an appropriate area. The invention also relates to a method for creating a surgical graft for a recipient site of a patient using the method for expanding human corneal endothelial cells, and the surgical graft prepared therefrom.
    Type: Grant
    Filed: April 30, 2007
    Date of Patent: November 18, 2014
    Inventor: Ray Jui-Fang Tsai
  • Method for treating damaged tissue of the CNS
    Patent number: 8883716
    Abstract: Devices and methods for treating diseases associated with loss of neuronal function are described. The methods are designed to promote proliferation, differentiation, migration, or integration of endogenous progenitor stem cells of the central nervous system (CNS). A therapy, such as an electrical signal or a stem cell enhancing agent, or a combination of therapies, is applied to a CNS region containing endogenous stem cells or a CNS region where the endogenous stem cells are predicted to migrate and eventually reside, or a combination thereof.
    Type: Grant
    Filed: December 7, 2011
    Date of Patent: November 11, 2014
    Assignee: Medtronic, Inc.
    Inventor: Lisa L. Shafer